Press release
Pulmonary Arterial Hypertension (PAH) Market to Hit US$ 13.5 Billion at a CAGR of 5.4% by 2028
Pulmonary Arterial Hypertension (PAH) Market
COVID-19 resulted in operational difficulties, delays in regulatory approvals, delays in clinical trials, restrictions on patient access, and a decrease in demand. Additional obstacles to the industry's growth included delays in diagnostic tests, updated hospital and emergency care guidelines, and a troubled drug supply chain.
Download Sample Copy of This Report -
https://www.factmr.com/connectus/sample?flag=S&rep_id=7234
Why is North America Expected to Lead the Pulmonary Arterial Hypertension Market?
North America is anticipated to hold a 35% market share for pulmonary arterial hypertension in 2022. It is projected that rising awareness, a high prevalence of diagnoses, and supportive governmental initiatives will drive market expansion in North America.
The presence of significant competitors and a carefully thought-out reimbursement scheme both support market growth. The demand for cutting-edge healthcare facilities for treating pulmonary arterial hypertension is being driven by the increasing prevalence of chronic and infectious diseases as well as a high diagnostic rate.
Key Companies Profiled
• Gilead Sciences Inc.
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novartis International AG
• Bayer HealthCare
• United Therapeutics Corp
What makes this Pulmonary Arterial Hypertension (PAH) market report distinct from others?
• Industrial trend analysis: The study examines the most recent developments in the Pulmonary Arterial Hypertension (PAH) arena, which are accompanied by advancements in technology and adjustments to business practises. The extent of these technologies is studied to help client companies comprehend the benefits and hazards connected with employing digital and industrial technologies in light of market trends.
• Sustainable metrics for pulmonary arterial hypertension (PAH) - The emphasis of this research is on fresh approaches to ensuring sustainability, which intensifies concern over environmentally friendly production and consumption. Among these insights are the eco-friendly initiatives that several industry companies have adopted. Customers are also informed of their contribution to sustainable development goals via information on a manufacturer's carbon footprint.
Get Full Access of Complete Report -
https://www.factmr.com/checkout/7234
Segmentation of Pulmonary Arterial Hypertension (PAH) Industry Research
• By Drug Class:
o Prostacyclin & Prostacyclin Analogs
o Endothelin Receptor Antagonists (ERAs)
o Phosphodiesterase-5 (PDE-5) Inhibitors
o Soluble Guanylate Cyclase (sGC) Stimulators
• By Pipeline Analysis:
o Early-stage Drug Candidates (Phase I & Phase II)
o Late-stage Drug Candidates (Phase III & Registration Phase)
• By Region:
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East & Africa
Check out more related studies published by Fact.MR Research:
https://www.newswire.co.kr/newsRead.php?no=948105
https://www.newswire.co.kr/newsRead.php?no=948532
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension (PAH) Market to Hit US$ 13.5 Billion at a CAGR of 5.4% by 2028 here
News-ID: 3097702 • Views: …
More Releases from Fact.MR
USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Develo …
The U.S. microbiome skincare market is projected to experience rapid, data-driven growth over the next decade, driven by rising consumer awareness, ingredient innovation, and the integration of personalized diagnostics. Analysts estimate the U.S. microbiome skincare segment at approximately USD 0.13 billion in 2025, with a projected increase to USD 0.35 billion by 2035, representing a compound annual growth rate (CAGR) of 10.4%.
To access the complete data tables and in-depth insights,…
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future …
The U.S. lubricants market is projected to experience steady growth through 2035, driven by shifts in mobility, industrial demand, and sustainability trends. The market was valued at approximately $41.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $52 billion by 2035.
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12463
…
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: K …
"Demand for intermodal freight transport connecting the UK and continental Europe is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising trade volumes, decarbonization mandates, and digital logistics innovations. The intermodal market, encompassing rail, short-sea shipping, and last-mile road delivery, is expected to handle over 18 million TEUs (twenty-foot equivalent units) annually by 2035, up from 10.2 million TEUs in 2025.
To access the complete…
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Fut …
The United States hydroxyapatite (HAp) market is projected to experience sustained, data-driven growth from 2025 through 2035, fueled by rising clinical demand, technological innovation, and expanded applications in regenerative medicine. Market modeling indicates that U.S. consumption of hydroxyapatite will nearly double over the next decade, with strong adoption in orthopedic, dental, and advanced biomaterial sectors.
To access the complete data tables and in-depth insights, request a Discount On The Report here:…
More Releases for PAH
Strategic Insights into the Pulmonary Arterial Hypertension (PAH) Market 2028
The global Pulmonary Arterial Hypertension (PAH) market was valued at USD 5.2 billion in 2020 and is anticipated to reach USD 13.5 billion by 2028, with a CAGR of 5.4% from 2021 to 2028.Research and development efforts, along with collaborative initiatives between healthcare professionals and governments, are propelling market growth amid the COVID-19 pandemic.Market stakeholders are focusing on effective and cost-efficient treatments for PAH patients, although lack of awareness regarding…
Pulmonary Arterial Hypertension (PAH) Market Trends and Forecast 2021-2028
Pulmonary Arterial Hypertension (PAH) Market: Overview
The pulmonary arterial hypertension (PAH) market is estimated to attain a valuation of US$ 13.5 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5.4% from 2021 to 2028.
The key objective of the TMR report is to offer a complete assessment of the global market…
Development: Pulmonary Arterial Hypertension (PAH) Market Growth Analysis
The global pulmonary arterial hypertension (pah) market is estimated to surpass $9,670.2 million by 2027, exhibiting a CAGR of 5.8% from 2020 to 2027.
The report provides all-inclusive analysis of global pulmonary arterial hypertension (pah) market with comprehensive study of the various facets of the market including market dynamics, major segments and regions, top leading players, and competitive landscape.
Research Methodology
Research Dive offers its clients extensive research and analysis gleaned from wide…
Pulmonary Arterial Hypertension (PAH) Market Research and Clinical Analysis 2020
Global Pulmonary Arterial Hypertension (PAH) Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters.
This Pulmonary Arterial Hypertension (PAH) Market research report identifies the competitive landscape of industries to understand the competition at International level.…
Pulmonary Arterial Hypertension (PAH) Medicine Market (2020-2027) Report Offers …
The research study includes the latest updates about the COVID-19 impact on the Pulmonary Arterial Hypertension (PAH) Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.
The market research report on the global Pulmonary Arterial Hypertension (PAH) Medicine market provides an extensive and…
Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Report 2017"
Description
In this report, the global Pulmonary Arterial Hypertension (PAH) Medicine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report split global into several key Regions, with sales (K MT),…
